Clinical Trials Using Obinutuzumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Obinutuzumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-25 of 32
1 2 Next >

  • Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

    This randomized phase II trial studies how well obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Umbralisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without umbralisib, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.
    Location: 297 locations

  • A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)

    This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory FL, and with rituximab, polatuzumab vedotin, and venetoclax in participants with DLBCL. Participants with FL who achieve complete response (CR), partial response (PR), or stable disease (SD) at the end of induction therapy will receive post-induction treatment with obinutuzumab and venetoclax, and participants with DLBCL who achieve CR or PR at the end of induction (EOI) will receive post-induction treatment with rituximab and venetoclax.
    Location: 6 locations

  • Obinutuzumab in Treating Patients with Central Nervous System Lymphoma Who Have Achieved a Complete Response

    This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response). Monoclonal antibodies, such as obinutuzumab, may kill cancer cells that are left after chemotherapy.
    Location: 6 locations

  • A Phase 1 / 2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

    Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and antiproliferative activity in CLL. CC-122 has also been shown to have a tolerable safety profile with some preliminary signs of efficacy with early human experience.
    Location: 6 locations

  • A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

    This study is a multicenter, open-label study of polatuzumab vedotin administered by intravenous (IV) infusion in combination with standard doses of bendamustine (B) and rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18 weeks for participants with DLBCL and 24 weeks for participants with FL.
    Location: 6 locations

  • Ibrutinib and Obinutuzumab in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

    This randomized phase Ib trial studies the side effects and best dose of obinutuzumab when given together with ibrutinib in treating patients with chronic lymphocytic leukemia that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Monoclonal antibodies, such as obinutuzumab, interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab with ibrutinib may work better in treating chronic lymphocytic leukemia.
    Location: 5 locations

  • Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

    Patients with high tumor burden, low grade follicular lymphoma that has never been treated, will receive venetoclax in combination with obinutuzumab and bendamustine. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with follicular lymphoma. Venetoclax may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see whether adding venetoclax to obinutuzumab and bendamustine improves the response (the tumor shrinks or disappears) in patients with follicular lymphoma.
    Location: 6 locations

  • Obinutuzumab and High-Dose Ibrutinib in Treating Patients with Progressive Chronic Lymphocytic Leukemia

    This phase II trial studies how well obinutuzumab and high-dose ibrutinib work in treating patients with chronic lymphoblastic leukemia that is growing, spreading, or getting worse. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and high-dose ibrutinib may work better in treating patients with chronic lymphoblastic leukemia.
    Location: 4 locations

  • A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R / R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R / R Diffuse Large B-Cell Lymphoma (DLBCL)

    This Phase Ib / II, open-label, multicenter, non-randomized, dose-escalation study will evaluate the safety, efficacy, and pharmacokinetics of obinutuzumab in combination with idasanutlin and venetoclax in participants with R / R FL and obinutuzumab or rituximab in combination with idasanutlin and venetoclax in participants with R / R DLBCL. The study will include an initial dose-escalation phase followed by an expansion phase. The dose-escalation phase is designed to determine the recommended phase II doses (RP2Ds) and regimen for idasanutlin and venetoclax in combination with obinutuzumab for FL participants and in combination with rituximab for DLBCL participants.
    Location: 3 locations

  • A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    This study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and lenalidomide in participants with relapsed or refractory (R / R) follicular lymphoma (FL) and rituximab in combination with polatuzumab vedotin and lenalidomide in participants with R / R diffuse large B-cell lymphoma (DLBCL), followed by post-induction treatment with obinutuzumab in combination with lenalidomide in participants with FL who achieve a complete response (CR), partial response (PR), or stable disease (SD) at end of induction (EOI) and post-induction treatment with rituximab plus lenalidomide in participants with DLBCL who achieve a CR or PR at EOI.
    Location: 3 locations

  • A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed / Refractory (R / R) Follicular Lymphoma (FL) and in Combination With Rituximab in R / R Diffuse Large B-Cell Lymphoma (DLBCL) Participants

    This is a open-label, mutlicenter, non-randomized, study to evaluate the safety, efficacy, and pharmacokinetics of idasanutlin in combination with obinutuzumab in participants with R / R FL and rituximab in combination with idasanutlin in R / R DLBCL. The study will include an initial dose-escalation phase followed by an expansion phase. The dose-escalation phase is designed to determine the recommended phase 2 dose (RP2D) for idasanutlin in combination with obinutuzumab for FL and in combination with rituximab for DLBCL. The expansion phase is designed to further assess the safety and efficacy of obinutuzumab in combination with idasanutlin at the RP2D with the selected regimen in participants with R / R FL and of rituximab in combination with idasanutlin at the RP2D in participants with R / R DLBCL.
    Location: 4 locations

  • Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

    The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of tirabrutinib (ONO / GS-4059) in combination with other targeted anti-cancer therapies in adults with relapsed or refractory B-cell lymphoproliferative malignancies. This study consists of two parts: Dose Escalation and Dose Expansion. During the dose escalation phase, participants will be sequentially enrolled in a standard 3 + 3 dose escalation study design, to receive oral tirabrutinib combined with idelalisib entospletinib + / - obinutuzumab. The Dose Expansion Phase will enroll additional participants with a single B-cell lymphoproliferative malignancy disease type to further evaluate efficacy, safety, tolerability, PK, and pharmacodynamics.
    Location: 2 locations

  • Phase 1b Safety and Efficacy Study of TRU-016

    The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in patients with CLL; and in combination with bendamustine in patients with PTCL.
    Location: 3 locations

  • Vemurafenib and Obinutuzumab in Treating Participants with Previously Untreated Classical Hairy Cell Leukemia

    This phase II trial studies how well vemurafenib and obinutuzumab work in treating participants with previously untreated classical hairy cell leukemia. Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib and obinutuzumab may work better in treating participants with previously untreated hairy cell leukemia.
    Location: 3 locations

  • A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R / R Follicular Lymphoma

    The purpose of the study is to evaluate the efficacy, safety and tolerability and of BGB-3111plus obinutuzumab versus obinutuzumab alone in subjects with relapsed / refractory non-Hodgkin follicular lymphoma.
    Location: 3 locations

  • Bendamustine and Obinutuzumab in Treating Patents with Previously Untreated Mantle Cell Lymphoma

    This phase II trial studies how well bendamustine and obinutuzumab work in treating patients with previously untreated mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving bendamustine and obinutuzumab may work better in treating patients with mantle cell lymphoma.
    Location: 2 locations

  • Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Treating Patients with Relapsed or Refractory B-Cell Lymphoma

    This phase Ib trial studies the best dose and side effects of venetoclax in combination with ibrutinib, prednisone, obinutuzumab and lenalidomide in treating patients with B-cell lymphoma that has come back or not responding to treatment. Drugs used in chemotherapy, such as venetoclax, prednisone and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving venetoclax in combination with ibrutinib, prednisone, obinutuzumab and lenalidomide, may work better at treating B-cell lymphoma.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients with Indolent Non-Hodgkin's Lymphomas

    This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Obinutuzumab, High Dose Methylprednisolone Sodium Succinate, and Lenalidomide in Treating Patients with Richter Syndrome

    This phase I trial studies the side effects of obinutuzumab, high dose methylprednisolone sodium succinate, and lenalidomide in treating patients with Richter syndrome. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as high dose methylprednisolone sodium succinate and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, high dose methylprednisolone sodium succinate, and lenalidomide may work better in treating patients with Richter syndrome.
    Location: University of California San Diego, San Diego, California

  • Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

    The purpose of this study is to evaluate the safety and efficacy of INCB050465 when combined with bendamustine and obinutuzumab in subjects with relapsed or refractory follicular lymphoma (FL).
    Location: 2 locations

  • Entospletinib and Obinutuzumab in Treating Patients with Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

    This phase I / II trial studies the side effect and best dose of entospletinib when giving together with obinutuzumab and to see how well they work in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma that has come back. Entospletinib may stop the growth of cancer cells by blocking some of the enzymes need for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Giving entospletinib and obinutuzumab together may work better in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkin lymphoma.
    Location: 3 locations

  • Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may work better in treating patients with B-cell non-Hodgkin lymphoma.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Atezolizumab, Obinutuzumab, and Ibrutinib in Treating Patients with Relapsed, Refractory, or Untreated High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This phase II trial studies how well atezolizumab, obinutuzumab, and ibrutinib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back after a period of improvement, does not respond to treatment, or is high-risk and untreated. Monoclonal antibodies, such as atezolizumab and obinutuzumab, may block cancer growth in different ways by targeting certain cells. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab, obinutuzumab, and ibrutinib may work better in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Obinutuzumab in Combination with Ibrutinib in Treating Patients with Relapsed Mantle Cell Lymphoma

    This phase II trial studies how well obinutuzumab works in combination with ibrutinib in treating patients with mantle cell lymphoma that has returned (relapsed) or that does not respond to treatment (refractory). Obinutuzumab binds to a protein called cluster of differentiation (CD)20, which is found on B cells and some types of leukemia and lymphoma cells and help the immune system kill cancer cells. Ibrutinib blocks a protein called Bruton’s tyrosine kinase (BTK), which may help keep cancer cells from growing. Giving obinutuzumab in combination with ibrutinib may kill more cancer cells.
    Location: OHSU Knight Cancer Institute, Portland, Oregon

  • Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia

    This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as obinutuzumab, block cancer growth in different ways by targeting certain cells. Giving ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab together may work better in treating chronic lymphocytic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas


1 2 Next >